STAT News

STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis

By STAT News

1 min read
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights